Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) has announced that it has regained compliance with Nasdaq's Minimum Bid Price Rule. The company's stock traded above $1.00 per share for ten consecutive trading days, meeting the requirement as of August 27, 2024. Shuttle Pharma, founded in 2012 by Georgetown University Medical Center faculty members, is a specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy.
The company's mission is to develop radiation sensitizers that enhance the effectiveness of radiation therapy while reducing side effects. Shuttle Pharma aims to increase cancer cure rates, prolong patient survival, and improve quality of life when used as a primary treatment or in combination with other therapies.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ha annunciato di aver riacquisito la conformità con la Regola del Prezzo Minimo delle Azioni del Nasdaq. Le azioni della società hanno commerciato sopra $1,00 per azione per dieci giorni di negoziazione consecutivi, soddisfacendo il requisito a partire dal 27 agosto 2024. Shuttle Pharma, fondata nel 2012 da membri della facoltà del Georgetown University Medical Center, è una società farmaceutica specializzata focalizzata su migliorare i risultati per i pazienti affetti da cancro sottoposti a radioterapia.
La missione della società è sviluppare sensibilizzatori alla radioterapia che aumentino l'efficacia della radioterapia riducendo al contempo gli effetti collaterali. Shuttle Pharma mira ad aumentare i tassi di guarigione del cancro, prolungare la sopravvivenza dei pazienti e migliorare la qualità della vita quando utilizzata come trattamento principale o in combinazione con altre terapie.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ha anunciado que ha recuperado la conformidad con la Regla de Precio Mínimo de Nasdaq. Las acciones de la compañía se negociaron por encima de $1.00 por acción durante diez días de negociación consecutivos, cumpliendo así con el requisito desde el 27 de agosto de 2024. Shuttle Pharma, fundada en 2012 por miembros de la facultad del Georgetown University Medical Center, es una empresa farmacéutica especializada centrada en mejorar los resultados para los pacientes con cáncer tratados con radioterapia.
La misión de la compañía es desarrollar sensibilizadores a la radioterapia que aumenten la efectividad de la radioterapia mientras reducen los efectos secundarios. Shuttle Pharma tiene como objetivo aumentar las tasas de curación del cáncer, prolongar la supervivencia de los pacientes y mejorar la calidad de vida cuando se utiliza como tratamiento principal o en combinación con otras terapias.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH)는 나스닥의 최소 입찰 가격 규정을 재준수했다고 발표했습니다. 이 회사의 주가는 2024년 8월 27일 기준으로 10일 연속으로 주당 $1.00 이상 거래되어 요구 사항을 충족했습니다. Shuttle Pharma는 2012년에 조지타운대학교 의학센터 교수들에 의해 설립된 전문 제약 회사로 방사선 치료를 받는 암 환자의 결과 개선에 집중하고 있습니다.
회사의 사명은 방사선 치료의 효과를 높이면서 부작용을 줄이는 방사선 감 sensibilizer를 개발하는 것입니다. Shuttle Pharma는 암 치료 성공률을 높이고, 환자의 생존 기간을 연장하며, 주 치료법 또는 다른 치료와 병행하여 사용할 때 삶의 질을 향상하는 것을 목표로 하고 있습니다.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) a annoncé qu'elle a récupéré la conformité avec la Règle sur le Prix Minimum des Actions de Nasdaq. Les actions de la société ont été négociées au-dessus de 1,00 $ par action pendant dix jours de négociation consécutifs, respectant ainsi l'exigence à partir du 27 août 2024. Shuttle Pharma, fondée en 2012 par des membres du corps professoral du Georgetown University Medical Center, est une entreprise pharmaceutique spécialisée axée sur l'amélioration des résultats pour les patients atteints de cancer traités par radiothérapie.
La mission de l'entreprise est de développer des sensibilisateurs à la radiothérapie qui renforcent l'efficacité de la radiothérapie tout en réduisant les effets secondaires. Shuttle Pharma vise à accroître les taux de guérison du cancer, à prolonger la survie des patients et à améliorer la qualité de vie lorsqu'il est utilisé comme traitement principal ou en combinaison avec d'autres thérapies.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) hat bekanntgegeben, dass es die Konformität mit der Mindestkursregel von Nasdaq wiedererlangt hat. Die Aktien des Unternehmens wurden an zehn aufeinanderfolgenden Handelstagen über $1,00 pro Aktie gehandelt und erfüllten die Anforderungen ab dem 27. August 2024. Shuttle Pharma, gegründet im Jahr 2012 von Fakultätsmitgliedern des Georgetown University Medical Center, ist ein spezialisiertes Pharmunternehmen, das sich auf die Verbesserung der Ergebnisse für Krebspatienten, die mit Strahlentherapie behandelt werden konzentriert.
Die Mission des Unternehmens besteht darin, Strahlensensibilisatoren zu entwickeln, die die Wirksamkeit der Strahlentherapie steigern und dabei Nebenwirkungen reduzieren. Shuttle Pharma zielt darauf ab, die Heilungsraten von Krebs zu erhöhen, die Überlebenszeit der Patienten zu verlängern und die Lebensqualität zu verbessern, wenn es als primäre Therapie oder in Kombination mit anderen Therapien eingesetzt wird.
- Regained compliance with Nasdaq Minimum Bid Price Requirement
- Stock traded above $1.00 per share for ten consecutive trading days
- None.
Shuttle Pharma's regaining of Nasdaq compliance is a positive development for the company's financial stability and investor confidence. Maintaining a listing on a major exchange like Nasdaq provides better access to capital and increased visibility for the stock.
However, it's important to note that this compliance was achieved just above the minimum threshold. The stock price hovering near
While this news averts an immediate delisting risk, it doesn't fundamentally change Shuttle Pharma's business outlook. The company's focus on radiation sensitizers in cancer treatment remains speculative and investors should evaluate the potential market size and competition in this niche area.
Shuttle Pharma's focus on developing radiation sensitizers for cancer treatment is an interesting niche in oncology. This approach aims to enhance the efficacy of radiation therapy, potentially improving patient outcomes.
However, the company's progress in this field remains unclear from the provided information. Investors should seek details on:
- The current stage of Shuttle Pharma's pipeline
- Any ongoing clinical trials
- Partnerships with established oncology players
The radiation sensitizer market, while promising, faces challenges in demonstrating significant improvements over standard radiation therapy. Shuttle Pharma will need to show compelling clinical data to gain traction in the competitive oncology landscape.
GAITHERSBURG, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Rule. Nasdaq sent notice to the Company that it had regained compliance as of August 27, 2024, after it traded above
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 21, 2024, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
FAQ
When did Shuttle Pharmaceuticals (SHPH) regain compliance with Nasdaq's Minimum Bid Price Rule?
What is Shuttle Pharmaceuticals' (SHPH) main focus in cancer treatment?
When was Shuttle Pharmaceuticals (SHPH) founded and by whom?
What are the goals of Shuttle Pharmaceuticals' (SHPH) radiation sensitizers?
